title: Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
abstract: Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.
authors.affiliation: Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Lucie M
authors.initials: LM
authors.lastname: Turcotte
authors.forename: Colleen K
authors.initials: CK
authors.lastname: Correll
authors.forename: Robyn C
authors.initials: RC
authors.lastname: Reed
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Moertel
mesh_terms: D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005871:Castleman Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors; D012074:Remission Induction
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; C502936:tocilizumab
keywords: CHOP; anakinra; multicentric Castleman disease; tocilizumab
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1485-8
references.pmid: 20501803
references.citation: Blood. 2000 Jan 1;95(1):56-61
references.pmid: 10607684
references.citation: Mol Cancer Ther. 2012 Aug;11(8):1623-6
references.pmid: 22638145
references.citation: Cancer Res Treat. 2009 Jun;41(2):104-7
references.pmid: 19707509
references.citation: Clin Nephrol. 2011 Feb;75(2):165-70
references.pmid: 21255547
references.citation: Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii119-25
references.pmid: 21602182
references.citation: Nephrol Dial Transplant. 2011 Feb;26(2):599-609
references.pmid: 20656751
references.citation: Am J Surg Pathol. 1995 Sep;19(9):1021-8
references.pmid: 7661275
references.citation: J Pediatr Hematol Oncol. 2008 Dec;30(12):920-4
references.pmid: 19131781
references.citation: Blood. 1989 Sep;74(4):1360-7
references.pmid: 2788466
references.citation: Blood. 2005 Oct 15;106(8):2627-32
references.pmid: 15998837